Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | HTR7 | P34969 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84899 | 0.78 | MAOA (0.44) | MAOANOS3NOS2MAPK10BCHE | |
| SCHEMBL6985896 | 0.78 | MAOA (0.44) | MAOANOS3NOS2MAPK10KDM4E | |
| SCHEMBL6983307 | 0.78 | NOS3 (0.45) | MAOANOS3NOS2MAPK10BCHE | |
| SCHEMBL6988233 | 0.76 | NOS3 (0.44) | NOS3NOS2 | |
| SCHEMBL6986291 | 0.76 | NOS3 (0.44) | NOS3NOS2 | |
| SCHEMBL6987417 | 0.74 | MAPT (0.54) | MAOANOS3NOS2MAPK10ALDH1A1 | |
| SCHEMBL6991272 | 0.74 | MAOA (0.42) | MAOANOS3NOS2MAPK10BCHE | |
| SCHEMBL5107 | 0.74 | ALDH1A1 (0.44) | KDM4EALDH1A1DNMT1 | |
| SCHEMBL29350037 | 0.74 | ALDH1A1 (0.44) | KDM4EALDH1A1DNMT1 | |
| SCHEMBL146878 | 0.74 | ALDH1A1 (0.44) | KDM4EALDH1A1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183378-B2 | Ligands, their preparation and uses thereof in asymmetric reactions | Li, Chao-Jun (CA) | 2012-05-22 | — | — | US | disclosed |
| US-8183378-B2 | Ligands, their preparation and uses thereof in asymmetric reactions | Li, Chao-Jun (CA) | 2012-05-22 | — | — | US | disclosed |
| US-20090247757-A1 | LIGANDS, THEIR PREPARATION AND USES THEREOF IN ASYMMETRIC REACTIONS | CHAO-JUN LI (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247757-A1 | LIGANDS, THEIR PREPARATION AND USES THEREOF IN ASYMMETRIC REACTIONS | CHAO-JUN LI (CA) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247757-A1 | LIGANDS, THEIR PREPARATION AND USES THEREOF IN ASYMMETRIC REACTIONS | OGFR, OR10J3, OPRL1 | MAOA 2801/4885NOS3 1412/4885NOS2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.